In restructuring roughly 40 percent of the company’s leadership, Ms. Walmsley hired people outside the company from various corporations, including Google and Novartis AG, and promoted select individuals from within, the London-based company said in an email to Bloomberg.
Ms. Walmsley said in July Glaxo must focus on developing treatments for respiratory conditions, HIV, and infectious and autoimmune disorders, as well as end or divest roughly 30 drug-development programs to spur long-term growth, according to the report.
More articles on supply chain:
6 drug, devicemakers in the headlines
Kick-start your supply chain in 2018: 3 New Year’s Resolutions
Drug charity stops financial assistance services following HHS scrutiny
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.